Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Common Equity came in at $66.4 million in Q1 2026, down 42.56% YoY from $115.6 million in Q1 2025, and down 10.52% on a QoQ basis from $74.2 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Common Equity data on file, last reported at $66.4 million in Q1 2026.
- Quarterly Common Equity fell 42.56% year-over-year to $66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.4 million (down 42.56% YoY) and the FY2025 annual result came in at $74.2 million, down 42.98% from the prior year.
- Common Equity slipped to $66.4 million in Q1 2026, from $74.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $254.8 million in Q2 2022 to a low of $66.4 million in Q1 2026.
- A 5-year average of $170.0 million and a median of $172.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 579.14% — and 2025, when it tumbled 47.03%.
- Tracing BRNS's Common Equity over 5 years: stood at $243.2 million in 2022, then decreased by 23.11% to $187.0 million in 2023, then plunged by 30.41% to $130.1 million in 2024, then sank by 42.98% to $74.2 million in 2025, then declined by 10.52% to $66.4 million in 2026.
- The last three Common Equity figures came in at $66.4 million (Q1 2026), $74.2 million (Q4 2025), and $84.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.79 Bn |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - | 57.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.13 Mn |
| Mar 31, 2026 | 66.40 Mn |
| Dec 31, 2025 | 74.21 Mn |
| Sep 30, 2025 | 84.47 Mn |
| Jun 30, 2025 | 102.48 Mn |
| Mar 31, 2025 | 115.59 Mn |
| Dec 31, 2024 | 130.14 Mn |
| Sep 30, 2024 | 159.46 Mn |
| Jun 30, 2024 | 156.79 Mn |
| Mar 31, 2024 | 172.02 Mn |
| Dec 31, 2023 | 187.00 Mn |
| Sep 30, 2023 | 195.60 Mn |
| Jun 30, 2023 | 217.46 Mn |
| Mar 31, 2023 | 233.57 Mn |
| Dec 31, 2022 | 243.20 Mn |
| Sep 30, 2022 | 244.15 Mn |
| Jun 30, 2022 | 254.77 Mn |
| Mar 31, 2022 | 253.14 Mn |
| Dec 31, 2021 | 252.56 Mn |
| Sep 30, 2021 | 242.47 Mn |